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Application of Ex-Vivo/3D 




COVID-19 treatment methods based on 3D organoids and ex-vivo platforms 
are analyzed in this chapter. Initially, the platforms available for cell culture and its 
working characteristics are explained. Subsequently discusses the organoids with 
their definition and included their uses in various applications. Further, the chapter 
extends to describe the uses of different organoids with their use in different stages. 
Most of these methods utilized the 3D ex-vivo cell culture method to develop organ-
oids and test them over infected tissues. Based on the study in this chapter, it is 
found that the demonstration of active replication of the human organoids culture 
system of lungs is found to be more helpful for COVID-19 treatment.
Keywords: COVID-19, 3D exvivo, 3D Organoid models, invivo, cell culture
1. Introduction
COVID-19 and SARS, such treatment drugs and vaccines, remains a challenge 
to predicting clinical reaction. Predicting clinical response to vaccines and drugs 
remains a challenge in any viral treatment such as COVID-19 and SARS. COVID-19,  
a sort of corona disease, created a pandemic danger situation caused due to 
newly raised virus. Predicting novel virus biology lies majorly in vitro models, as 
it permits viral replication. Animal and human organoids had raised their value in 
the experimental virology platform. COVID-19 is a killing disease that increased 
the death rate of human beings higher than influenza. The number of reported 
cases is more or less equal to the number of deaths. Similarly, the infection mortal-
ity rate tends to increase deaths to 1%. This disease was most leniently spread from 
person to person through contacts or even through the respiratory system. There are 
different approaches taken to solve this dreadful disease which took away the lives 
and livelihood of millions worldwide. One such research approach is by gearing 
towards the direction of 3D organoids and ex-vivo platforms. 3D organoid models 
and ex-vivo platforms are known to recreate the disease-specific and organ-specific 
microenvironment in the lab. These models are well studied in cancer research [1].
Studies indicated that using 3D organoid and ex vivo models at an early stage 
of virus research might help them from failure. Most organoids can be established 
from induced pluripotent stem cells (IPSC), commonly containing 3D structure. 
Also, it consists of cell types for the specific organ, and multipotent adult tis-
sue stem cells can create an organoid. To predict tissue tropism of this emerged 
COVID-19, various research groups ought to get the help of an organoid approach 
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for preventing gastric tract and kidney failure. COVID-19 directly infected capil-
lary organoids and kidney organoids. This chapter describes 3D ex-vivo organoid 
enabled stem cell culture for prediction, helping to combat COVID-19. Using ex 
vivo platforms to predict the response for vaccines is important before it reaches 
clinical trials. Subsequently, treatment for tumors with an inhabitation induced 
activation, but all tumors failed to induce an antitumour response in a subset; 
likewise, COVID-19 drugs fail to give antiviral activity. Thus, it is important to use 
precision ex vivo models [2].
While new infection disease emerged, virologists expose indicator cell lines 
panel. From a typical human origin or monkey origin to patient materials and find 
for viral replication signs. Species barriers get complicated due to this trial-and-
error approach. In the indicator panel, it was also done by the potential absence of 
a target. Recently severe acute respiratory syndrome due to coronavirus, organoids 
termed research emphasizes the value of more physiological in vitro models. In 
Wuhan city novel coronavirus disease 2019 (COVID-19) outbreak began that 
quickly transmitted everywhere china and to various parts of the domain in all 
countries. This spread of COVID-19 resulted in an extensive pandemic. Numerous 
treatment methods have been established for these diseases. As stated, earlier 
vaccines for this disease were not yet developed. Organoids are newly generated 
patterns developed from human stem cells, ex vivo duplicating process drug, and 
viral screening process for infection models. Self-categorized tissues are commonly 
seen in human organoids, which contain the different structure of cells. Cells that 
contain the same structure of cell functions as real organs for a human being. This 
pattern permitted viral infection efficiency and resulted in experimentation.
Areas unmet with COVID 19 research about leveraging this organoid method 
tends to help us predict the effect of this disease in tissues concerning organs. It 
will be an efficient tool for assisting researchers in predicting disease in the lab and 
helping to improve in development of a drug for COVID 19. It deciphers pathways 
for biomarker by keeping in mind that coronavirus is the fastest spreading disease, 
particularly for those with a weak immune system. Studying and understanding 
the effect of COVID 19 with the help of this platform in this increasing population 
is essential for regular therapeutics improvement in this field. They are focusing on 
miniature organ research at the lab to study coronavirus’s progress in the human 
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kidney, and lungs to the liver. Experiments are conducted using drugs with the help 
of these mini tissues for identifying the working of these therapies would be can-
didates for treating people. Experts understand that SARS-Cov-2 might have a side 
effect on organs in the human body from residing infected persons. Unfortunately, 
there is no proper statement about this damage directly affected by the virus to 
secondary complications of infection. Various groups with the help of organoid 
to represent in body virus, cell infects that cause damages [3, 4]. Splender of 3D 
ex vivo organoids recreates human microenvironment in true lab morphology of 
tissues. An overview of COVID-19 diagnosis and management is shown in Figure 1.
2. Nuts and bolts of 3D organoid and ex-vivo models
3D structures of organoids are placed from induced pluripotent stem cells, 
and also multipotent adult tissue stem cells are substituted. Organize themselves 
via spatially restricted for containing specific-organ cell types and cell sorting 
lineage commitment to creating cell assembly with permanent tissue architec-
tural and functional characteristics. Typically, it consists of complement varied 
cell types that are present in interesting organs. Standardized organoid models 
since designed from cell sources that is extended from a wide amount of time. 
Organoids that depend on ipsc initially during cell population that permits certain 
extension. For generating organoids, given that ipsc permitted to form a human 
body and signals that takes through an execution developed to duplicate continu-
ous improvement, brain or kidney organs are interested terms followed in vivo. 
Fully identified stem cells that taken straight from tissue, so the Establishment of 
ASC extracted organoids is complex. Smoothly design whole organoid structure 
several growth factors like tissues such as culturing and mouse gut in one cocktail. 
It involves active stem cells of relevant kinds of cells. Mainly organoids in other 
tissues are expanded by the proliferation of the progenitor cells and the ASCs in 
rich growth factors. The cell structure necessary to reduce the growth factor levels 
can be driven to adopt them [5].
3. Current approach on combat COVID 19
Some low-limit nations with similarly powerless wellbeing frameworks and 
restricted ability to balance the monetary and social expenses of populace level 
physical removal, incorporating a few nations with wellbeing framework deli-
cacy and very weak populaces, presently announce inconsistent cases, bunches 
of cases, and network transmission. The window for control at the subnational 
and public level might be shut in many of these nations. Individuals living in 
aggregate destinations are powerless against COVID-19 to a limited extent as a 
result of the wellbeing hazards related to development or uprooting, stuffing, 
expanded climatic presentation because of the unacceptable sanctuary, and 
poor nourishing and wellbeing status among influenced populaces. Albeit, a few 
variations of site plans may not be achievable. Augmenting site getting ready for 
better removing among occupants and group the executives, adherence to con-
tamination counteraction and control principles, solid danger correspondence 
and network commitment, and a decent observation framework to distinguish 
starting cases early can significantly decrease the inclination for COVID-19 to 
spread inside such settings. Proper case, the board can lessen mortality among 
those tainted with the infection. The Interim Guidance plots the essential strides 
to guarantee these limits are set up.




Samples of saliva often included more SARS-CoV-2 copies than swab samples, 
and up to 10 days after initial diagnosis, a larger fraction of Saliva samples were 
positive. And in 495 health care professionals’ testing, two more asymptomatic 
cases were recognized as Swab’s. The scientists concluded in their letter that these 
data confirm the potential for detecting SARS-CoV-2 infection are used saliva speci-
mens. At least saliva seems comparable with nasopharyngeal swabs in regulated 
health care environments. However, COVID-19 is a global epidemic, with rural, 
disadvantaged or otherwise under deployed communities most afflicted. And such 
situations can affect the way saliva-based tests perform [6].
3.1.2 Polymerase chain reaction (PCR) test
PCR tests were also taken while affected by the Covid-19 virus. PCR accurately 
discover the occurrence of an antigen instead of bodily presence antibodies or 
immune responses. PCR test will find out at the initial stage of health patients has 
affected by virus based on recognizing the viral RNA, before antibodies generation, 
which will be available in the body illness signs occur. The general welfare authori-
ties might better understand the transmission of disease, like Covid-19, among a 
population by using PCR testing to monitor huge bundles of Nasopharyngeal swab 
tests from within a populace.
3.1.3 Serologic testing
After Covid-19, how long immunity retro will be staying in the body is indeter-
minate. Previous numerous researches have illustrated, who survived the epidemic 
of SARS (Acute Rapid Air Syndrome) those peoples had antibodies in their body for 
long eons afterwards retrieval. In several cases, after affected diseases, immunity 
will be increased naturally. Still, if Covid-19 causes a comparable immunological 
reaction, it would be untimely to say that coronaviruses produce Covid-19 and 
SARS. Nowadays, specific patients again affected by covid-19. This represents that 
these patients did not get immunity in their body naturally, which was displayed in 
several kinds of research. For antibody tests, such as the PCR tests, which usually 
use swabs to identify Covid-19, blood samples are normally needed. There seems to 
be little coronavirus but substantial and quantifiable antibody presence, circulating 
throughout the blood linked with the respiratory tract.
3.2 Antibody treatment
A SARS-CoV-2 alteration that enables the virus to avoid detection using differ-
ent COVID-19 therapies produced antibodies which are proved by much research. 
Modern medicines termed monoclonal antibodies are shown with immunological 
molecules that are naturally produced. Jesse Bloom and his team mapped all prob-
able SARS-CoV-2 mutations at the Fred Hutchinson Cancer Research Laboratory 
in Seattle, Washington, that were likely to impede binding with three monoclonal 
antibodies. One was made by Indiana, Eli Lilly in Indianapolis, and the second was 
made in a cocktail prepared in Tarrytown, New York by Regeneron. The receptor-
binding element is the Alterations that impair a protein fragment interacting and 
entering cells by the virus. The researchers detected an alteration that caused the 
virus to elude the identification of one of the three antibodies with Regeneron’s 
5
Application of Ex-Vivo/3D Organoid Models in COVID-19 Research
DOI: http://dx.doi.org/10.5772/intechopen.99100
antibodies cocktail. Not many of these changes are generally circling in tainted 
individuals. In every case, one is frequent in Europe and one in Denmark and 
Netherlands, where cases of mink and individuals working in mink ranching have 
been reported in SARS-CoV-2. The discoveries have not yet been peer-inspected.
3.3 Antiviral drugs
Fluvoxamine, Umifenovir, camostat, ritonavir, Famotidine, Nafamostat, 
Lopinavir, hydroxychloroquine and chloroquine are drugs that are testing for 
medication of COVID-19. The treatment for SARS-CoV-1 and the Covid, which 
induce respiratory disorders for the Middle East, was successfully proved in vitro 
tests. However, there was no testing that confirmed that equal SARS-CoV-2 activity 
component. Nafamostat and camostat are antagonists of serine proteases. Camostat 
was already reported to prevent SARS-CoV entrance by acting as a researcher and 
serine protease inhibitor TMPRSS2 suggest together camostat, and nafamostat may 
inhibit SARS-CoV-2. Russia and China have licensed for use only as Umifenovir, 
and this is a tiny prophylactic indole derivative compound for influenza A and 
B viruses. Thiazolidine is Nitazzoxanide used in parasitic, bacterial and viral 
contamination as a viable enemy of an infectious disease. Several bio-informatics 
approaches can be used in detecting the sequence of the virus [7]. Scientists are also 
working to counteract potential “cytokine storms” in some patients that cause lung 
harm and severe respiratory discomfort. As stated early, for covid-19, there is no 
vaccines or drugs for the treatment. Hence some methods may predict this disease 
and take treatments to reduce its severeness and stop spreading to other persons. 
Some of them are discussed below.
3.4 COVID-19 interferons
Interferons are anti-inflammatory proteins and natural broad-spectrum anti-
viral that induce signaling pathway followed by transformation of IFN-stimulated 
genes and bind to their receptors on the surface of various cells [8]. It includes an 
antiviral enzyme and also pro-inflammatory components. These are a group of 
cytokines and are primarily developed from infected cells and immune cells. These 
activated immune cells perform the killing of infected cells and also deactivate 
movement of the virus in the human body. This method is helpful during the 
early prediction of diseases, and hence treatment can happen with ease. While 
implementing interferon at the early-stage amount of infections in the beginning 
stage prompts decreases, disease duration is short. However, as mentioned earlier, 
there are no vaccines for Covid-19. Hence prevention is the only way to safeguard. 
Covering mouth during cough, wearing mask, washing hands rapidly, and a safe 
distance from each other might help. However, this method helps an average person 
with a better immune system and does not favor elderly persons and infants.
4. Combat COVID-19 using emerging organoids and ex vivo platforms
A human ex-vivo model affirmed the significance of NK cells in medication 
prompted demise under pressure in formerly led tests [9]. These discoveries 
focussed on an intermingling between drug-initiated obstruction and tumor-
resistant contexture. Be that as it may, sympathetic to the science behindhand 
this viral reproduction, infection system medication disclosure endeavors are 
restricted because of the absence of an appropriate test model. Previously, single-
cell RNA sequencing data of human organoids to explore explanations of ACE2 and 
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TMPRSS2, despite an assortment of RNA receptors to investigate their capacity in 
SARS-CoV-2 pathogenesis, were used. ACE2 is abundant in all organoids, besides 
the prostate and brain, and TMPRSS2 is omnipresent [1]. Natural, secure pathways 
in all organoids with the exception of the lungs are expanded in ACE 2(+) cells. 
Inquisitively, ACE2 (+) of the digestive tract, lung and retinal organoids have an 
extending low-thickness lipoprotein receptor with a more prominent joint in lung 
organoids. This investigation uncovers that organoids could be utilized for the 
review of this new pollution component and for the improvement of medications as 
a logical stage. General organoid application is shown in Figure 2.
4.1 3D organoids and virology
For acute gastroenteritis, human norovirus is the main cause. The primary 
drawback for the development of efficient therapy for norovirus is the absence of 
a powerful in vitro contamination model. Co-workers of Estes find the transfer 
of virus to gut enterocytes and its cell type is unavailable from cell lines intestine. 
Rather it was found in organoids. In ASC inferred enterocytes, little intestinal 
societies allowed development with different human norovirus strains. It ended up 
being an extra mind boggling factor. Mechanism of pathogenesis find organoids, 
where ipsc based organoids techniques are unique, and also it permits key aspect 
modeling for human brain development. While it happened during the Zika virus 
epidemic, it notably had an association between severe abnormalities and ZIKV 
infections. It does not affect the brain, and sequential studies used human cerebral 
organoids handled over causation proof. Replication of ZIKV in brain development 
and preferably affects and killed neural precursors.
It caused obstacles to microcephaly4 and cortical extension4. Similarly, 
organoids may be employed to reveal explicit species powerlessness differences. 
Pig H1N1 and Avian H7N2 flu infections mostly contaminate winged animals and 
pigs, separately, yet purported ‘reassortant’ flu infections. H1N1 virus (H1N1pdm) 
spread out speedily through human populaces. In the last periods, robust in vitro 
models are not available. The uses of ex vivo bronchus manipulating organizations 
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by these transitory bronchus explant cultures. Hui et al. [10] the expected rep-
lication capacity, tropism in the tissue and the generation of cytokines inducing 
bronchi- and human-aviation pathways organoids from human and avian strains 
of flu. These tests provide appropriate findings by using organoids and explants. 
Considering organoids may be enlarged over the eons and removed from airways 
and frozen, organoids were considered to be beneficial for assessing the pandemic 
risk of animal flu infections. This end was confirmed by an equal report. Zhou et al. 
[11] human aviation ways organoids generate wide tug cultures, here it involves a 
few considerable aviation ways epithelial cells categories such as club cells, basal 
cells, ciliated cells and flagon cells. Two sets of infections with a clearly identified 
infectiveness in individuals were provided to these organoids. The coordinated 
contagions that ineffectually infectious in peoples by imitated two infections of 
people were further comprehensive.
4.2 Organoid types
4.2.1 Gut organoids
Multiple organs are joined to generate the spinal tract, which arises from a 
rudimentary general tube that is elaborated between the mouth and the anus. 
The gut tube [10] has endodermal layer pillage, which has a three-region subdivi-
sion. Hindgut, midgut and Foreskin, where each location in the development of 
the embryonal layer produces certain organs throughout specific intervals. The 
Pancreas, stomach, liver, esophagus, Pharynx and part of the duodenum have also 
been raised by foregust. This portion is generated as 3D organoids from a mouse 
that depicts intestinal SC, which arise in a rich lamina madrigal from the structures 
of crypt-villus and all the primary cell types of the gut [12]. The biomedical plat-
form uses Intestinal organoid technology for forskolin-induced human organoid, 
which permits the cellular structure of drug investigation. By isolating the colon, 
organoids grow superficially into a single-layer epithelium with notions of auto 
surgery that have injured the mouse colon [13, 14].
4.2.2 Organoids of liver
The liver comes from the extension of the foregut ventral wall that has been 
conceived to the structure of the liver bud. Hypoblasts described as hepatic endo-
derm cells formed from this bud, and both sinusoidal endothelial cells provide an 
estimate of the surrounding environment and mesenchyme. Hepatic vasculature 
is developed in conjunction with the development of liver bud, which forms a 
vasculogenesis and angiogenesis combination. It turns into a primary hematopoietic 
foetal organ. Therefore, the liver is designed based on the sensitive orchestration 
of signals between mesenchymal, endothelial and endodermal signals before the 
perfusion of the blood. 3D liver organoids designed for the treatment of liver failure 
are produced and assisted. The development of 3D organoids contributes to the 
development of epithelial liver bodies [15–17].
4.2.3 Organoids of kidney
Mesodermal origins are mostly in the metanephric kidney and generate the back 
of the trunk. The organogenesis starts with the defined intermediate mesoderm of 
the kidney precursor tissue, leading to mesonephric and epithelial mesenchyme 
and monitoring the rostral-caudal direction. Uteric bud is a new epithelial protru-
sion in the development of a branched collecting tube structure that invades and 
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interacts with the neighboring MM. In the same way, mature nephrons and other 
MM derivatives cause MM differentiation, epithelization and condensation through 
progressive MM. The signals and branches are regulated. It is obvious before the 
other organs that the kidney tissue can be self-organized from previous research 
with reaggregation.
4.2.4 Organoids of brain
The neural ectoderm formed a neural plate system, which generates a flat lamina 
of ectodermal cells positioned in close contact with the embryo and gradually builds 
a cylindrical epithelial structure called a neural tube [11]. The stringent spatial–
temporal gradient of morphogens allows for the epithelial tube to be separated into 
four prosencephalons, mesencephalon and rhombencephalon areas with rostral-
caudal axes and ventral-dorsal axes. Here prosencephalon emerges from secondary 
vesicles and creates the diencephalon and telencephalon. Neural stem cells that 
are followed by organoids generate glia and CNS neurons. Rostro caudally resides 
in the neural tube, and symmetrical simulation also asymmetrical simulations 
are continually initialized. NSC also provides more segmented cell structures to 
self-renewing progenitors, which include interim progenitors and neurons. Mostly 
distinct cells move outside the NSC domain, creating multi-layered structures such 
as the cerebral cortex, optic tectum and the medulla [18–20].
4.2.5 Organoids of retina
The retina is a light open area of the eye and digests from neural ectoderm, and 
retinal primordia emerge from the diencephalon that evaginates along the side. This 
produces pseudo-stratified neuro-epithelia, called optical vesicles, which turns into 
a sensory neural retina in its distant section. Proximal segment offers to begin to cash 
layered tissue and melanin delivered retinal shade epithelium, and OVs go through 
invagination at their distal part that frames an optic cup with RPE and NR as its external 
and internal dividers as for one another. NR comprises PC that is isolated from ganglion 
cell design, cones and bars alongside strong cell types. This vertebrate retina is created 
as 3D organoids and utilized as a most remarkable reaggregation model in tissue design-
ing for examining the neural layer at its fundamental. This examination was led in chick 
embryos and archived that supplanted retina performed with a surprising limit with 
respect to reassembling them as different round types with the entire plan [21–23].
Since COVID-19 has an extremely rapidly distributed worldwide channel for 
infection, it is still not favorable for pathogenic mechanisms. A disease model 
is essential for the study of the pathological characteristics of virus infection 
or drug prediction. In viral infection research, 2D models are most frequently 
utilized. However, in an ex vivo context, it was unable to imitate and search 
reliability was limited. The large distance between human beings and primates is 
a disadvantage for these species. Broncho-alveolar resections using lavage mate-
rial are extracted from airway organoids. The procedure was helpful and can be 
modified for drug screening for beyond 1 year. The system includes mesenchy-
mal cells, human-derived and endothelial. In the human liver environment, it 
was highly stimulated. For a consistent structure, intercellular interactions such 
as tight connections are needed. Additional organoids are notified that not only 
microvilli, bile capillaries and lipid droplets in hepatic cells are dedicated to more 
human organoids in LO. It is substantially more distinct from LO than in cells 
like the liver generated by human beings [24].
A precondition for suspect ability due to viral infection without considering as in 
vivo or in vitro. A prerequisite for questionable ability to develop in vivo or in vitro due to 
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viral infection. Human pluripotent stem cell reveals lung markers, extracted from 3D 
LBO’s
 
, , . , , , , ,8 2 1 1 1 10 63EPCAM KRT NKX FOXA FOXJ CC mucins and P .
These LBOs showed growing, detachment and wretchedness tantamount to 
human lungs when the respiratory syncytial infection is contaminated. Contrasted 
with essential human hepatocytes, Na + −taurocholate co-shipping polypeptide, an 
HBV section receptor, was higher in human iPSC-LOs, which showed high helpless-
ness to HBV contamination. Factors also increase the efficiency of infection, such as 
, ,5GPC PPARA and CEBPA,
 
which were higher in human iPSC-Los. 
, , , ,HBV pgRNA intercellularvDNA cccDNA and supernatantvDNA  are the 
infection in human iPSC-LOs. It is present at a higher level than human iPSC-like 
cells [25].
During previous periods the improvement of organoids has shown as a 
revolution. Lung organoids, the invention of human intestinal organoids and 
human organs, are assent with the help of adult stem cell (ASC). The ASC also 
proved by the above-indicated organs. Once the separated intestinal organoids 
are produced, the multi-cellular structure and efficient complication of human 
intestine epithet are precisely mimicked for more than a year. The human 
gastrointestinal system is the widely used path of microbial attack. In vitro 
models for the study of intestinal illnesses have been shown to be popular in 
humans. In past studies, many studies were done to show an ASC culture of 
an intestine organoid epithelial bat. The possible source of SARS-CoV-2 is 
empirically linked to suggested bat organoids [26, 27]. The likelihood of enteric 
disease is investigated using SARS-CoV-2 in human intestinal organoids. The 
use of Crypts separated from the intestines in R Sinicus bats has been explored 
in SARS-CoV-2 and SARSr-breakout CoV’s in fecal horseshoe bat species to 
evaluate high distinguishing features of SARS-CoV and SARSr-CoVs. It devel-
oped bat small bowel organoids (enteroids), which use the methodology to 
make human bowel organoids. In the environment expanding and in a ratio of 
1:2 every seven days, the indistinguishable bat entereroids are grown. In order 
to facilitate separation, the expansion medium was converted into a differentia-
tion media during which enteroids are incubated for 4 days. The developed 
enteroids in bat replicate the multicellular structure of the native bat’s small 
intestinal epithelium. Employing electrical transmission microscopy, cells 
with typical characteristics of four important bat-enteroid intestinal cell kinds 
such as, enteroendocrine (EE) cells, paneth (P) cells, goblet (G), and includ-
ing enterocytes (E) were found. Although one line of bat entereroids has been 
spread sequent for 12 weeks, the other lines, unlike human intestine organoids, 
stopped active production for at least 1 year following the passage for 4 or 
5 weeks. It recognized the first bat intestinal organoid to imitate the bat intesti-
nal epithelium cellular makeup [28].
4.3 Culturing of organic airways and isolation of human lung cells
The non-tumor lung tissue generated from patients in resection with pulmonary 
fluids was extracted from human lung stems. Human spherical organoids of 50 to 
200 μm have been produced from pulmonary stem cells and lung parenchymatic 
cells. Rganoid and ex-vivo cultures belonged to the same 3 donors aged between 
55 and 69 years. Every single donor was produced from a single line. Scalpel lung 
tissue with a laundry of 10 ml of DMEM, 10 mm HEPES and 1% of Glutamax media 
and F12 media penicillin–streptomycin solution. The ling tissue type 2 mg/mL ling 
tissue has been digested for one hour at 37°C on a shaking platform (St. Louis, MO, 
USA, Sigma-Aldrich).
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The residual tissue parts and the Filter suspension were repeatedly sheared 
with Glutamax, 10 mM HEPES, and 1% penicillin streptomycin solution using a 
100 μm filter with 10 mL complete DMEM and F12 media. The filtrate was then 
collected in a 50 mL bottle with 2% foetal serum bovine. Then the remaining 
volume is centrifuged for 5 minutes at 4°C at 600rcf. Lysis buffer Red blood cells 
lysed at room temperature for 5 min (Roche, Basel, Switzerland). Cut the whole 
DMEM/F12 media into a 10 mL cell pellet and centrifugate the pellet at 600rcf 
for 5 min. Matrigel will obtain human airway organoids during 14 days using cul-
tivated. The Cultrex growth factor of cellular membrane type 2 matrix Culturex 
cell membrane (Gaithersburg, Trevigen, MD, United States) is reduced by the 
40 μL droplet from cell membranic membrane extract cell suspension at 35°C 
for 15–30 min to solidify pre-heated 24-well suspension platforms with a 10 mg/
mL lung cell. Each well was filled with 500 μL of organoid media and incubators 
with 5 percent CO2 at 37°C. The new organoid medium has taken on mechanical 
cutting with a 1000uL pipette and flamed Pasteur pipettes every four days. Every 
two weeks, the organoids were transported. The entire DMEM/F12 medium was 
added 10 mL, and organoids were centrifuged for 5 min at 450 rcf. The fragments 
are seeded in 1:1–1:6 proportions, and the fragmented organic fragmentation is 
replaced in a cold matrigel [29–31].
Human airway organoids are ready for infection at 37°C after 14 days at 5 
percent CO2. Organoid matrigel with organoids comprising a number of organoids 
of the growth agent. Reactive substances and concentration for each growth factor. 
While less common than respiratory symptoms, gastrointestinal disorders have 
occurred in a considerable proportion of people with COVID-19. For a group of 
73 COVID-19 patients, 53% had SARS-CoV-2 RNA in stool, with stool remaining 
positive even if breathing trials were negative with RNA viruses in 23% of patients. 
Viral NP-positive cells have been found in the gastrointestinal epithelial cells of 
these biopsy patients’ tissues. Persistent fecal disposal was especially prominent 
in pediatric patients. Taken together, these clinical findings show that COVID-19 
patients may get enteric infections. This shows, however, that a new pathway for the 
virus can be the human digestive system [32, 33].
5. Advantages and disadvantages of ex vivo and 3D platforms
Does not need animal care after operation in an ex-vivo instrument is valu-
able, permits more duplicability between lesions and gives the regeneration 
experiment a rigorously regulated artificial air [26]. Ex vivo models of the spinal 
cord include cultivation for up to three weeks of several hundred micron-sized 
crosspieces. Ex vivo methods specifically secluded perfused lung enjoys a benefit 
of generally controlled dosing complex multicellular reaction physiological 
openness productive utilization of material. It additionally shows certain restric-
tions. For example, it was, in fact, requesting, and it has a short perception 
time. Another method, to be specific accuracy cut lung cut, enjoys the benefit of 
controlled cell portion, complex multicellular reaction, and effective utilization 
of material. It additionally has certain weaknesses of non-physiological open-
ness and short perception time. Impediments of ex vivo treatment incorporate 
incidental unite mass of numerous cell types like fibroblasts and astrocytes. 
One more prevalent constraint of ex vivo is that hereditary change is proper 
for secret modules that can digest cellularly information and does not help for 
remedial modules that assisted with entering objective cells. It is comparably 
huge not to make sham longings, and moreover to address two indispensable 
issues that swarm the majority of the current organoid systems: a shortfall of 
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reproducibility and, coupled to this, our shortfall of cognizance of the cycles that 
deal with their development.
6. Future perspective of 3D culture, organoid models in COVID research
In its earliest phases, the creation of 3D organoid products from human PSCs 
has now advanced rapidly. Soon human organoids can be produced for organisms 
already developed in the mouse or when re-aggregation investigations have already 
demonstrated a source of self-orientation. The skin, mammary gland, muscle and 
bone are part of it [27]. Organ expansion models since organoids show a model 
approach that is plainly available and allow them to open up doors to increasingly 
complicated or unachievable issues that have been resolved through conventional 
approaches. This applies in particular to biological concepts specific to people. For 
particular, the particular class approach of human neural stem cells has already 
been studied with human brain organoids. Retinal organoids have also been used 
for testing changes between morphogenesis and timing of human and rodent tissue. 
In addition, GI tract organoids can also be employed to investigate the organized 
promotion of GI bodies, a method that shows crucial human change combined with 
animal laboratory. Organoids are also promising to model homosexuality for adults. 
The relevance of the crypt niche in stem-cell self-renovation and differentiation was 
previously studied by intestinal organoids. This applies primarily to organoids from 
adult progenitors such as the liver and stomach, which closely recreate regeneration 
processes seen in the adult organ. Although if numerous options of organoids are 
clear, it is important to remember their existing limitations. In the recapitulation of 
in vivo development, all organoid approaches that have been shown so far remain 
meticulously defined. For example, whereas retinal organoids finely show classical 
laminar composition, external parts do not shape; photoreceptors, for example, are 
short of being entirely developed to become light sensitive.
Consequently, brain organoids [34] recapitulate fast brain growth outcomes, 
but future features, for example, in cortical platelets, are not fully formed. The 
development issue appears to be a common impediment to organoid technologies 
and whether this will limit their research and therapeutic opportunities greatly 
is still to be explored. In the end, the lack of vascularization is usually an in vitro 
problem for organoids. Organoids have limited growth capacity, which may also 
impact their development because of nutrition supply restrictions. A whole subject 
of tissue engineering that has been tackled by the various techniques of vasculariza-
tion. Spinners can provide healthier nutritional swaps with a size of up to a few 
millimeters in this example of organoids. Instead, endothelial cell co-culture can 
create systems like vascular systems. However, the transplantation of these tissues 
is possibly the most hopeful problem-solve, as was done with liver buds and kidney 
organoids that fosters hosts invasion [35, 36].
Organoids have significant potential as a way of drug testing and therapy for 
development and disease modeling. Potential initiatives will certainly get them 
closer to this prospect.
7. Conclusion/summary
In this chapter, a discussion about COVID-19 treatment methods based on 3D 
techniques was briefly analyzed. In the first section, platforms that are available 
for cell culture and its working characteristics were discussed. Later, it continu-
ously discussed organoids, their definition, and their uses in different applications. 
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Further, its use as different organs is described with its use in different stages. 
Prediction, as well as treating COVID-19, was found to be crucial and also, research 
plays a major role to put forth hybridizing of any two methods for accurate cur-
ing of COVID-19 from a human body. This method utilized 3D exvivo cell culture 
method to develop organoids and replace them over infected tissues. 3D disease 
models are previously available invitro and invivo technologies. However, they 
showed certain limitations and hence, treating viral infection using any stem cell 
culture and 3D technologies are quite helpful. Summarizing this chapter is based on 
the demonstration of active replication of human organoids culture system of lungs 
are found to be more helpful in the treatment of COVID-19. An organoid culture 
system is previously proposed and then used in a variety of applications. Rather it 
implemented 3D technologies for the development of cell culture and then replaced 
defective cells for an effective cure of viral infection.
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